Advice
following a full submission:
linzagolix (Yselty®) is accepted for restricted use within NHSScotland.
Indication Under Review: the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.
SMC restriction: for use in patients when conventional first-line treatments (such as tranexamic acid, hormonal contraceptives and intrauterine devices) have failed or are considered unsuitable.
Treatment with linzagolix, with and without hormonal add-back therapy (ABT), resulted in statistically significant and clinically meaningful reductions in menstrual blood loss, compared with placebo.
Medicine details
- Medicine name:
- linzagolix (Yselty)
- SMC ID:
- SMC2631
- Indication:
For treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age
- Pharmaceutical company
- Theramex UK LTD
- BNF chapter
- Obstetrics, gynaecology, and urinary-tract disorders
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 11 November 2024